Introduction. Endothelial dysfunction has been considered as one of the important factors in pathogenesis of Metabolic Syndrome (Met S). Subclinical hypothyroidism (SCH) has also been reported to be associated with Met S. The aim of our study is to evaluate the association of raised TSH with mediators of endothelial dysfunction in Met S with Subclinical hypothyroidism as compared to healthy controls.
Methods. Study population consisted of 100 subjects, out of which 50 were cases of Met S and 50 were healthy controls. Met S group were further divided into two, based on the presence & absence of SCH. Serum insulin, T3, T4, TSH were measured by chemiluminescence based immunoassay (CLIA). Serum nitric oxide (NO) levels were measured by Modified Griess’s method and serum endothelin-1 (ET-1) levels were measured by ELISA.
Results. Out of 50 cases of Met S, SCH was diagnosed in 22. The mean serum TSH levels were significantly higher in Met S cases as compared to healthy controls (5.7 ± 1.2 μIU/mL vs. 2.3 ± 1.6 μIU/mL, P <0.0001). Mean serum NO levels were significantly lower in Met S cases as compared to healthy control (15.4 ± 10 μM vs. 21 ± 10 μM, p = 0.009). Mean serum ET-1 levels were significantly higher in Met S cases as compared to healthy controls (2.68 ± 1.7 fmol/mL vs. 2.1 ± 0.84 fmol/mL, p = 0.011). On Pearson’s correlation analysis, TSH showed positive correlation with ET-1 (r = 0.341, p = 0.001) and negative correlation with NO (r = −0.331, p = 0.001). Binary logistic regression analysis showed that TSH, NO and ET-1 has significant odd’s ratio for predicting Met S.
Conclusion. Met S cases were screened for thyroid abnormalities and found to have 44% of SCH along with co-existing endothelial dysfunction. Raised TSH in SCH could cause endothelial dysfunction which may lead to Met S and associated co-morbidities. Present study gives new insight in linking endothelial dysfunction and raised TSH in Met S. Therefore, Met S cases should be screened for SCH and treated appropriately to attenuate endothelial dysfunction and associated comorbidities in Met S.
1. AHIRWAR AK., JAIN A., GOSWAMI B., BHATNAGAR MK., BHATACHARJEE J. Imbalance between protective (adiponectin) and prothrombotic (Plasminogen Activator Inhibitor-1) adipokines in metabolic syndrome. Diab Met Syndr: Clin Res Rev. 2014; 8 (3):152-5.
2. ALBERTI G., ZIMMET P., SHAW J., GRUNDY SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation. 2006 Nov 8:1-23.
3. MOZUMDAR A., LIGUORI G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011 Jan 1; 34 (1):216-9.
4. PRASAD DS., KABIR Z., DASH AK., DAS BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: A community study from urban Eastern India. Journal of cardiovascular disease research. 2012 Sep 30; 3 (3):204-11.
5. TZIOMALOS K., ATHYROS VG., KARAGIANNIS A., MIKHAILIDIS DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutrition, Metabolism and Cardiovascular Diseases. 2010 Feb 28; 20 (2):140-6.
6. HADI HA., CARR CS., SUWAIDI JA. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vascular health and risk management. 2005 Sep; 1 (3):183.
7. NIKNAM N., KHALILI N., KHOSRAVI E., NOURBAKHSH M. Endothelial dysfunction in patients with subclinical hypothyroidism and the effects of treatment with levothyroxine. Advanced biomedical research. 2016; 5.
8. MATHEW F., GLENDA J., JACK L. Quantification of nitric and nitrate in extracellular fluids. Metho Enzymol 1996; 268:237-46.
9. La Vignera S., Condorelli R., Vicari E., Calogero AE. Endothelial dysfunction and subclinical hypothyroidism: A brief review. J Endocrinol Invest. 2012; 35 (1): 96-103.
10. CABRAL MD., TEIXEIRA P., SOARES D., LEITE S., SALLES E., WAISMAN M. Effects of thyroxine replacement on endothelial function and carotid artery intima-media thickness in female patients with mild subclinical hypothyroidism. Clinics. 2011; 66 (8):1321-8.
11. AHIRWAR AK., JAIN A., SINGH A., GOSWAMI B., BHATNAGAR MK., BHATACHARJEE J. The study of markers of endothelial dysfunction in metabolic syndrome. Horm Mol Biol Clin Invest. 2015; 24 (3):131-6.
12. BALZAN S., DEL CARRATORE R., NICOLINI G., BEFFY P., LUBRANO V., FORINI F et al. Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. The Journal of Clinical Endocrinology & Metabolism. 2012 Mar 14; 97 (5):1763-70.
13. MEHRAN L., AMOUZEGAR A., RAHIMABAD PK., TOHIDI M., TAHMASEBINEJAD Z., AZIZI F. Thyroid Function and Metabolic Syndrome: A Population-Based Thyroid Study. Hormone and Metabolic Research. 2017 Mar; 49 (03):192-200.
14. TIAN L., ZHANG L., LIU J., GUO T., GAO C., NI J. Effects of TSH on the function of human umbilical vein endothelial cells. Journal of molecular endocrinology. 2014 Apr 1; 52 (2):215-22.
15. TÜREMEN EE., ÇETINARSLAN B., SAHIN T., CANTÜRK Z., TARKUN I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocrine journal. 2011; 58 (5):349-54.
16. DARDANO A., GHIADONI L., PLANTINGA Y., CARACCIO N., BEMI A., DURANTI E et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2006 Oct; 91 (10):4175-8.
17. ITO A., TSAO PS., ADIMOOLAM S., KIMOTO M., OGAWA T., COOKE JP. Novel mechanism for endothelial dysfunction. Circulation. 1999 Jun 22; 99 (24):3092-5.
18. NOFER JR., VAN DER GIET M., TÖLLE M., WOLINSKA I., VON WNUCK LIPINSKI K., BABA HA. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P 3. The Journal of clinical investigation. 2004 Feb 15; 113 (4):569-81.